Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.74%
1,098.14
-8.22
-0.74%
—1,106.361,105.681,109.291,096.52——
SIXC
Communications
SIXC
Communications
SIXC
+0.36%
612.51
+2.22
+0.36%
—610.29610.29616.60610.29——
SIXE
Energy
SIXE
Energy
SIXE
+0.70%
1,219.66
+8.44
+0.70%
—1,211.221,211.011,222.361,208.50——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.37%
1,757.13
+6.42
+0.37%
—1,750.711,753.101,762.131,743.30——
SIXM
Financials
SIXM
Financials
SIXM
+0.66%
632.29
+4.12
+0.66%
—628.17629.38634.09629.38——
SIXR
Staples
SIXR
Staples
SIXR
+0.24%
856.66
+2.09
+0.24%
—854.57855.71860.09855.45——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.51%
215.76
-1.11
-0.51%
—216.87216.87217.79215.51——
SIXT
Technology
SIXT
Technology
SIXT
+1.71%
3,622.77
+60.83
+1.71%
—3,561.943,571.443,628.583,562.15——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.43%
907.21
+3.88
+0.43%
—903.31903.26907.28901.18——
SIXV
Health care
SIXV
Health care
SIXV
+0.02%
1,481.82
+0.28
+0.02%
—1,481.541,482.481,488.461,474.18——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.00%
2,400.05
+0.10
+0.00%
—2,399.952,404.452,418.812,398.09——
ALNOV:EPA
Novacyt SA
€0.52
-18.75%
(-0.12) 1D
May 14, 5:35:10 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNOV...
Open
€0.58
High
€0.60
Low
€0.50
Mkt. cap
37.15M
Avg. vol.
1.20M
Volume
5.35M
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
216
News stories
From sources across the web
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees216
FoundedJul 3, 2006
Headquarters-
SectorBiotechnology
Websitenovacyt.com
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
4.90M
4.90M
5.12M
5.12M
Cost of goods sold
1.64M
1.64M
2.06M
2.06M
Cost of revenue
1.64M
1.64M
2.06M
2.06M
Research and development expenses
1.02M
1.02M
1.03M
1.03M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.51M
5.51M
5.24M
5.24M
Operating expense
6.43M
6.43M
14.13M
14.13M
Total operating expenses
8.08M
8.08M
16.19M
16.19M
Operating income
-3.18M
-3.18M
-11.07M
-11.07M
Other non operating income
-31.00K
-31.00K
2.67M
2.67M
EBT including unusual items
-3.51M
-3.51M
-10.16M
-10.16M
EBT excluding unusual items
-3.12M
-3.12M
-10.55M
-10.55M
Income tax expense
-133.50K
-133.50K
-1.81M
-1.81M
Effective tax rate
3.80%
3.80%
17.85%
17.85%
Other operating expenses
-97.50K
-97.50K
7.86M
7.86M
Net income
-3.17M
-3.17M
-8.27M
-8.27M
Net profit margin
-64.76%
-64.76%
-161.60%
-161.60%
Earnings per share
-
-
-
-
Interest and investment income
177.00K
177.00K
-
-
Interest expense
-154.00K
-154.00K
-2.09M
-2.09M
Net interest expenses
23.00K
23.00K
-2.09M
-2.09M
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.17M
-2.17M
-2.80M
-2.80M
Gain or loss from assets sale
-147.50K
-147.50K
-3.00K
-3.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer